Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2014-12-23 Regulatory Filings
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-1. It is a formal communication related to a securities registration process, not a financial report or detailed filing. The document length is short (2187 characters) and it does not contain financial data or report content. It is essentially a regulatory filing related to the registration process, not the registration statement itself or a report. Therefore, it fits best under Regulatory Filings (RNS).
2014-12-23 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 5 to Form S-1 Registration Statement filed with the SEC, dated December 23, 2014. It is a registration statement under the Securities Act of 1933 for AmpliPhi Biosciences Corporation. The text includes details about the registration of common stock shares for sale by selling stockholders, information about the company, risk factors, use of proceeds, selling stockholders, plan of distribution, dividend policy, dilution, market price, management discussion and analysis, business description, management, executive compensation, legal matters, and consolidated financial statements. This is a typical filing for a company registering securities for public offering, not a financial report or earnings release. The document is a registration statement amendment, which falls under the category of Capital/Financing Update (CAP) as it relates to fundraising and securities registration activities.
2014-12-23 English
Regulatory Filings 2014
Regulatory Filings
2014-12-19 English
DEF 14A
Proxy Solicitation & Information Statement
2014-11-25 English
Regulatory Filings 2014
Regulatory Filings
2014-11-24 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 4 to Form S-1 Registration Statement filed with the SEC, dated November 19, 2014. It is a registration statement under the Securities Act of 1933 for AmpliPhi Biosciences Corporation. The text includes details about the registration of common stock shares, offering price, registration fee, and other regulatory disclosures typical of an S-1 filing. It also contains a prospectus summary and detailed company information, including risk factors, management discussion, and financial statements restatement notes. This type of document is a capital raising filing related to the company's initial or secondary public offering, not a financial report, earnings release, or management report. Therefore, it fits the category of Capital/Financing Update (CAP).
2014-11-19 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.